Login to Your Account

Oncothyreon shares stumble as tecemotide trips

By Michael Fitzhugh
Staff Writer

Tuesday, August 19, 2014

Oncothyreon Inc. shares fell 17.3 percent Tuesday after the company revealed that tecemotide, an immunotherapy it licensed to Merck KGaA, failed to improve overall survival or impact secondary endpoints progression-free survival, time to progression or time to failure in a phase I/II study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription